In this exclusive MedPage Today video, Nicholas Short, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses the results with ponatinib (Iclusig) and blinatumomab (Blincyto) ...

Long-term morbidity varies by chemotherapy regimen, with higher odds of worse renal impairment seen with EPx4 versus BEPx3 ...

Certain chemotherapy regimens can lead to temporary or permanent infertility. Chemotherapy is a cornerstone of cancer treatment, renowned for its ability to eliminate cancer cells. However, the potent ...

As researchers keep looking for ways to deescalate treatment in HER2-positive breast cancer, a trial from China looked at a chemotherapy-free regimen with endocrine therapy, a CDK4/6 inhibitor, and ...

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when ...

A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an ...

Please provide your email address to receive an email when new articles are posted on . A targeted therapy/immunotherapy combination improved outcomes vs. standard treatment for newly diagnosed ...

Cedars Sinai tool predicts the best chemotherapy regimen for advanced pancreatic cancer using AI analysis of biopsy images.

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy. Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) ...